| 14 Patents Sami Said Are listed on Google Patent Search Why VIP is perfectly suited for the Treatment of SARS-CoV-2
VIP Research Papers From ARDS to Cancer
Link to Spreadsheet
Cell Entry Mechanisms of SARS-CoV-2
Cell entry mechanisms of SARS-CoV-2 “To fulfill its function, SARS-CoV-2 spike binds to its receptor human ACE2 (hACE2) through its receptor-binding domain (RBD) and is proteolytically activated by human proteases. Here we investigated receptor binding and protease activation of SARS-CoV-2 spike using biochemical and pseudovirus entry assays. Our findings have identified key cell entry mechanisms of SARS-CoV-2. First, SARS-CoV-2 RBD has higher hACE2 binding affinity than SARS-CoV RBD, supporting efficient cell entry. Second, paradoxically, the hACE2 binding affinity of the entire SARS-CoV-2 spike is comparable to or lower than that of SARS-CoV spike, suggesting that SARS-CoV-2 RBD, albeit more potent, is less exposed than SARS-CoV RBD. Third, unlike SARS-CoV, cell entry of SARS-CoV-2 is preactivated by proprotein convertase furin, reducing its dependence on target cell proteases for entry.”
Oswald Cruz Foundation in Brazil Abstract
The neuropeptides VIP and PACAP inhibit SARS-CoV-2 replication in monocytes and lung epithelial cells, decrease the production of proinflammatory cytokines, and VIP levels are associated with survival in severe Covid-19 patients. “The neuropeptides VIP and PACAP, which are members of the Secretin/Glucagon family of peptides, share many biological properties through their interaction with the G protein-coupled receptors VPAC1, VPAC2 and PAC115. PACAP binds to all three receptors, with higher affinity to PAC1, while VIP interacts preferentially with VPAC1 and VPAC215,16. VIP and PACAP are produced by Th2 CD4+ and CD8+ T cells17–19, and their receptors are expressed by a variety of cell types, including T cells, macrophages and dendritic cells15. “ List of Pro’s For Holding RLFTF long • Relief Therapeutics owns the patent to RLF100 and the process for synthesizing it.
• Relief Therapeutics has demonstrated some very very compelling results against COVID19
• RLF100 inhibits the virus from attaching to host cells in the lungs, AND…RLF100 Therapeutics prevents both Bradykinin and cytokine reducing inflammatory response before it begins, negating steroid use potentially
• Relief Therapeutics are already determined safe by the FDA.
• Relief Therapeutics intravenous RLF100 was submitted for EUA on 9/17 – awaiting FDA approval.
• Relief Therapeutics RLF100 clinical trials have reached the interim 102 patients on 9/30 – awaiting results.
• Relief Therapeutics clinical trial for the RLF100 treatment inhaler has been designed, submitted, and is expected to finish this year.
• Relief Therapeutics clinical trial for the RLF100 PREVENTATIVE inhaler has been designed, submitted, and is expected to finish next year.
• Relief Therapeutics show promise for other lung applications beyond Covid, which also need to be studied and tested separately
• Relief Therapeutics signed a Cooperative Agreement with NIH’s Institute of Arthritis and Infectious Diseases to test RLF-100 against the flu virus and other viruses that attack the lungs.
• Relief Therapeutics signed a contract with Bachem Americas to manufacture drug substance for 1 million patients.
• Relief Therapeutics signed a contract with Nephron Pharma to manufacture enough RLF100 for 1 million patients.
• Relief Therapeutics signed a contract with the largest supplier of inhaled sterile drugs in the United States to supply RLF-100 to any US hospital overnight.
• Relief Therapeutics obtained Companionate Care Protocol in Israel and we’re in the process of determining how to service it.
• NeuroRX’s CEO Dr. Javitt is ranked among the top 1% of quoted scientists worldwide, has successfully taken 7 drugs through the FDA process, and has served in key leadership roles under presidents Clinton, Bush Jr, Bush Sr, and Reagan.
• NeuroRX’s Chief of Operations, Robert Bestoff spent his career at Lilly & Pfizer. At Pfizer, he was head of the entire neuro science and pain division, responsible for $10B of their drugs.
• NeuroRX’s Manufacturing Coordinator, Rich Siegel, is the former head of Johnson & Johnson’s drug portfolio. | Raghuram (Ram) Selvaraju, Ph.D., MBA
contact@relieftherapeutics.com
media
Anne Hennecke / Brittney Sojeva
MC Services AG
relief@mc-services.eu
Ph: +49 (0) 211-529-252-14 Chairman of the Board Raghuram (Ram) Selvaraju
Vice Chairman Dr Jonathan Javitt
Board Member Peter De Svastic
Board Member Thomaz Burckhardt
Scientific Advisory Board Yves Sagot
Chief Medical Officer Gilles Della Corte, M.D.
Chief Financial Officer Jack Weinstien
- FINRA Broker Check
- Linkd’n
- Prepared DD Document Unfinished
VP of Finance & Administration Jeremy Meinen
Relief Insider Trades
9/17/2020 Gael Hedou 1462 Yvond Switzerland “ Beneficial Owner” Purchased Shares 16,375,998
Financial Statements
2020 Half Year Report Relief Therapeutics
Published 9/15/2020 Auditor’s Mazars RLFTF Share information from OTCBQ Certification Plus additional New Issues | RLFTF Share Information for primary OTCB Traded Security as of: August 18, 2020 | | FROM Page 1: RLFTF - OTCQB Listing Certification
Date August 18, 2020 | | Shares Authorized | (A) | 4,458,998,544 | | Total Shares Outstanding | (B) | 2,383,168,581 | | Number of Restricted Shares | (C) | 0 | | Unrestricted Shares Held by Officers, Directors, 10% Contro l Persons & Affiliates | (D) | 906,359,296 | | Public Float: Subtract Lines C and D from Line B | (E) | 1,476,809,285 | | % Public Float: Line E Divided by Line B (as a %) | (F) | 62.0% | | Number of Beneficial Shareholders of at least 100 shares | (G) | 7'209 | | Current Market Capitalization @ $0.58 per Share | 0.58 | $1,382,237,777 | | NEW ISSUES | | | | 9/28/2020 Relief Announces Capital Increase from its Final Tranche of the Share Subscription Facility with GEM | PR | 196,900,000 | | | Current Total OS Shares | 2,580,068,581 | | | | | | From Page 3: RLFTF - OTCQB Listing Certification
Date August 18, 2020 | | Name | City & State Or Country | Shares Owned | Options (converted in 60 days) | Warrants (converted in 60 days) | % of Class of shares owned | | GEM Global Yield Fund LLC SCS Beneficial Shareholder: Christopher Brown, New York | Luxembourg | 730,744,258 | | 666,658,667 | 30.66% | | Yves Sagot | France | 164,626,313 | 10,000,000 | | 6.91% | | Thomaz Burckhardt | Switzerland | 10,845,725 | | | 0.46% | | Jeremy Meinen | Switzerland | 143,000 | | | 0.01% | | | | 906,359,296 | 10,000,000 | 666,658,667 | 38.03% | | | | | | | | | History of Relief Therapeutics THERAMetrics Holding AG - Was Ticker TMX on Swiss SIX “MondoBIOTECH Holding AG” Changes name to THERAMetrics Holding AG MondoBiotech 6/20/2013 MondoBiotech holding AG changes name Therametrics Holding AG “ The company changed its name from mondoBIOTECH holding AG to THERAMetrics holding AG as at 20 June 2013” Notes to the Financial Statements see 1. General Information Page 7 Mondobiotech 4/12/2012 Mondobiotech Investor Presentation 10 Orphan Drugs in EU and US
19 Patents Granted
81 medicinal Products candidates
22 patent Families filed
312 Peptides to Redirect in Rare disease Table 7. Mondo Biotech Patents Table 8. Mondobiotech Orphan Drug Designation
4/5/2012 Annual Report Mondobiotech 2011 Page 10 Unlisted Companies - mondoBIOTECH Europe SA, Stans Clinical Development
mondoBIOTECH AG, Stans Licensing Out
mondoBIOTECH Laboratories AG, Vaduz Economic and scientific conception of the new approaches in the healthcare and in the IT area, and their intellectual property protection
mondoBIOTECh, Inc., Palo Alto Currently no operating activities
Fast TakeTOf AG, Stans Currently no operating activities
TheraNostics GmbH, München In liquidation
mondoBIOTECH US Inc., New York Currently no operating activities RLF-100 Aviptadil Patent Information *Note RLF-100, was acquired by RELIEF THERAPEUTICS Holding SA (Swiss Exchange: RLF, OTCBB: RLFTF) from the business combination of RELIEF THERAPEUTICS Holding SA and Therametrics Holding AG in January 2016. THERAMetrics holding AG formerly was known as MondoBIOTECH holding AG. Possible IP in Patents Below are a list of General searches on Mondobiotech, Thereametric and Relief Patents on Google PAtent Search and at WIPO patent search. Without legal evaluation they are to be considered only searches and not authority on whether the patents are the IP of “Relief Therapeutics Holdings AG” (RLFTF)
86 MondoBiotech AG patents Spreadsheet
WIPO IP PORTAL PAtentscope Search = Mondobiotech Total Hits 898 - RSS |